GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (NAS:ATAI) » Definitions » ROC (Joel Greenblatt) %

ATAI Life Sciences NV (ATAI Life Sciences NV) ROC (Joel Greenblatt) % : -3,166.41% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ATAI Life Sciences NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3,166.41%.

The historical rank and industry rank for ATAI Life Sciences NV's ROC (Joel Greenblatt) % or its related term are showing as below:

ATAI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -200308.7   Med: -38923.81   Max: -1724.41
Current: -1724.41

During the past 5 years, ATAI Life Sciences NV's highest ROC (Joel Greenblatt) % was -1724.41%. The lowest was -200308.70%. And the median was -38923.81%.

ATAI's ROC (Joel Greenblatt) % is ranked worse than
74.46% of 1468 companies
in the Biotechnology industry
Industry Median: -334.375 vs ATAI: -1724.41

ATAI Life Sciences NV's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


ATAI Life Sciences NV ROC (Joel Greenblatt) % Historical Data

The historical data trend for ATAI Life Sciences NV's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV ROC (Joel Greenblatt) % Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-38,923.81 -200,308.70 -109,386.36 -20,607.67 -2,181.66

ATAI Life Sciences NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16,322.21 -6,927.66 -4,947.14 7,645.15 -3,166.41

Competitive Comparison of ATAI Life Sciences NV's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, ATAI Life Sciences NV's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ATAI Life Sciences NV's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where ATAI Life Sciences NV's ROC (Joel Greenblatt) % falls into.



ATAI Life Sciences NV ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 5.334) - (18.052 + 0 + 1.351)
=-14.069

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.078) - (18.744 + 0 + 1.101)
=-15.767

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of ATAI Life Sciences NV for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-70.516/( ( (2.25 + max(-14.069, 0)) + (2.204 + max(-15.767, 0)) )/ 2 )
=-70.516/( ( 2.25 + 2.204 )/ 2 )
=-70.516/2.227
=-3,166.41 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ATAI Life Sciences NV  (NAS:ATAI) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


ATAI Life Sciences NV ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description

Traded in Other Exchanges
Address
Wallstraße 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Executives
Florian Brand officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Anne Nagengast Johnson officer: Chief Accounting Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Apeiron Investment Group Ltd. 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Sahil Kirpekar officer: Chief Business Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Stephen Bardin officer: Chief Financial Officer C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Michael Auerbach director 158 HESTER STREET, APT 7F, NEW YORK NY 10013
Amir H Kalali director 4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121
Christian Angermayer director, 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Rosnay Alexis De director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Srinivas Rao officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sabrina Martucci Johnson director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Camm director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Presight Ii, Lp 10 percent owner C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014